SCHEMBL1833487

SCHEMBL1833487

N#CCCc1cccc(C(F)(F)F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.66
KMT2A Q03164 1/20 0.66
TAAR1 Q96RJ0 1/20 0.61
MIF P14174 2/20 0.55
IDO1 P14902 2/20 0.50
HTR2A P28223 2/20 0.49
HTR2B P41595 2/20 0.49
HTR2C P28335 1/20 0.49
ACP3 P15309 1/20 0.47
DAO P14920 2/20 0.47
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
MAOB P27338 2/20 0.45
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
ADRA2C P18825 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9212090 0.90 TAAR1 (0.57) MEN1KMT2ATAAR1MIFIDO1
SCHEMBL30645106 0.90 TAAR1 (0.57) MEN1KMT2ATAAR1MIFIDO1
SCHEMBL10681526 0.83 MEN1 (0.58) MEN1KMT2ATAAR1MIFACP3
SCHEMBL5541700 0.82 TAAR1 (0.61) MEN1KMT2ATAAR1MIFIDO1
SCHEMBL38024 0.81 TAAR1 (0.55) MEN1KMT2ATAAR1MIFIDO1
SCHEMBL30096354 0.81 TAAR1 (0.55) MEN1KMT2ATAAR1MIFIDO1
SCHEMBL9106607 0.79 LTA4H (0.47) MEN1KMT2AALDH1A1MAOB
SCHEMBL11825679 0.78 TAAR1 (0.56) MEN1KMT2ATAAR1MIFIDO1
SCHEMBL14549528 0.77 TAAR1 (0.75) TAAR1MIFIDO1HTR2AHTR2B
SCHEMBL4716530 0.77 TAAR1 (0.55) MEN1KMT2ATAAR1MIFIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406211-B1 A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF MEGAFINE PHARMA P LTD (IN) 2018-06-27 EP disclosed
US-20150152040-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof AMNEAL PHARMACEUTICALS LLC (US) 2015-06-04 US disclosed
US-20150152040-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof AMNEAL PHARMACEUTICALS LLC (US) 2015-06-04 US disclosed
US-8969623-B2 Method for the preparation of cinacalcet and intermediates and impurities thereof Amneal Pharmaceuticals, LLC (US) 2015-03-03 US disclosed
US-8969623-B2 Method for the preparation of cinacalcet and intermediates and impurities thereof Amneal Pharmaceuticals, LLC (US) 2015-03-03 US disclosed
US-20140081048-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof MEGAFINE PHARMA (P) LTD. (IN) 2014-03-20 US disclosed
US-20140081048-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof MEGAFINE PHARMA (P) LTD. (IN) 2014-03-20 US disclosed
US-8575395-B2 Method for the preparation of cinacalcet and intermediates and impurities thereof Amneal Pharmaceuticals, LLC (US) 2013-11-05 US disclosed
US-8575395-B2 Method for the preparation of cinacalcet and intermediates and impurities thereof Amneal Pharmaceuticals, LLC (US) 2013-11-05 US disclosed
US-8455700-B2 Method for producing phenylalkane-1-ols BASF SE (DE) 2013-06-04 US disclosed
WO-2007127449-A1 PROCESS FOR THE PREPARATION OF CINACALCET BASE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-11-08 WO disclosed
US-20070259964-A1 Process for the preparation of cinacalcet base TEVA PHARMACEUTICALS USA, INC. 2007-11-08 US disclosed
US-20070259964-A1 Process for the preparation of cinacalcet base TEVA PHARMACEUTICALS USA, INC. 2007-11-08 US disclosed
US-20070260091-A1 Process for the preparation of cinacalcet base TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-11-08 US disclosed
US-7250533-B2 Process for preparing Cinacalcet hydrochloride TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) 2007-07-31 US disclosed
US-7250533-B2 Process for preparing Cinacalcet hydrochloride TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) 2007-07-31 US disclosed
US-20070043243-A1 Process for preparing Cinacalcet hydrochloride TEVA PHARMACEUTICALS USA, INC. 2007-02-22 US disclosed
US-20070043243-A1 Process for preparing Cinacalcet hydrochloride TEVA PHARMACEUTICALS USA, INC. 2007-02-22 US disclosed
WO-2006125026-A2 PROCESS FOR PREPARING CINACALCET HYDROCHLORIDE TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2006-11-23 WO disclosed
EP-0316733-A1 2-Amino pyrazolin-5-one BAYER AG (DE) 1989-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259964-A1 Process for the preparation of cinacalcet base KRAS, CA9, CA4 MEN1 30/4885KMT2A 553/4885TAAR1 4215/4885
US-20140081048-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof CMA1, SI, ALDH1A1 MEN1 587/4885KMT2A 1217/4885TAAR1 1331/4885
US-20070260091-A1 Process for the preparation of cinacalcet base KRAS, CA9, SI MEN1 30/4885KMT2A 625/4885TAAR1 4124/4885
US-20070043243-A1 Process for preparing Cinacalcet hydrochloride SI, PRCP, CA9 MEN1 116/4885KMT2A 2904/4885TAAR1 4836/4885
US-20150152040-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof CMA1, SI, ALDH1A1 MEN1 587/4885KMT2A 1217/4885TAAR1 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.